BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 14755389)

  • 1. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graphical search for two-stage designs for phase II clinical trials.
    Jung SH; Carey M; Kim KM
    Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the estimation of the binomial probability in multistage clinical trials.
    Jung SH; Kim KM
    Stat Med; 2004 Mar; 23(6):881-96. PubMed ID: 15027078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval estimation of binomial proportion in clinical trials with a two-stage design.
    Tsai WY; Chi Y; Chen CM
    Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curtailed two-stage designs in Phase II clinical trials.
    Chi Y; Chen CM
    Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.